Article
Lessons from the Failure to Complete a Trial of Denosumab in Women With a Pathogenic BRCA1/2 Variant Scheduling Risk-Reducing Salpingo-Oophorectomy.
Cancer prevention research (Philadelphia, Pa.) - 1 Nov 2022
Trivedi Meghna S, Arber Nadir, Friedman Eitan, Garber Judy E, Holcomb Kevin, Horowitz Neil S, Wright Jason D, Lee J Jack, Vornik Lana A, Abutaseh Saba, Castile Tawana, Sauter Edward R, Dimond Eileen, Heckman-Stoddard Brandy M, House Margaret, Samimi Goli, Brown Powel H, Crew Katherine D
Abstract excerpt
Female carriers of pathogenic/likely pathogenic (P/LP) BRCA1/2 variants are at increased risk of developing breast and ovarian cancer. Currently, the only effective strategy for ovarian cancer risk reduction is risk-reducing bilateral salpingo-oophorectomy (RR-BSO), which carries adverse effects related to early menopause. There is ongoing investigation of inhibition of the RANK ligand (RANKL) with denosumab as a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.